Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.
Fintel reports that on October 28, 2025, Citigroup maintained coverage of Vertex (NasdaqGM:VERX) with a Neutral recommendation. Analyst Price Forecast Suggests 51.14% Upside As of September 29, 2025, ...
Discover the magic of compounding and why it's important for increasing wealth Robert Kelly is managing director of XTS Energy LLC, and has more than three decades of experience as a business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback